Felipe A. Martínez

32.6k total citations · 8 hit papers
100 papers, 7.9k citations indexed

About

Felipe A. Martínez is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Felipe A. Martínez has authored 100 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Cardiology and Cardiovascular Medicine, 67 papers in Endocrinology, Diabetes and Metabolism and 28 papers in Surgery. Recurrent topics in Felipe A. Martínez's work include Diabetes Treatment and Management (60 papers), Heart Failure Treatment and Management (53 papers) and Cardiovascular Function and Risk Factors (36 papers). Felipe A. Martínez is often cited by papers focused on Diabetes Treatment and Management (60 papers), Heart Failure Treatment and Management (53 papers) and Cardiovascular Function and Risk Factors (36 papers). Felipe A. Martínez collaborates with scholars based in United States, United Kingdom and Argentina. Felipe A. Martínez's co-authors include James D. Neaton, Barbara Roniker, Marjorie Gatlin, Jay H. Kleiman, Richard M. Bittman, Faı̈ez Zannad, Bertram Pitt, Willem J. Remme, John J.V. McMurray and Scott D. Solomon and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Felipe A. Martínez

94 papers receiving 7.6k citations

Hit Papers

Eplerenone, a Selective Aldosterone Blocker, in Patients ... 2003 2026 2010 2018 2003 2003 2022 2009 2019 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
    2003 3.4k citations Bertram Pitt, Faı̈ez Zannad et al. profile →
  2. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION
    2003 539 citations James D. Neaton, Felipe A. Martínez et al. profile →
  3. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
    2022 491 citations Muthiah Vaduganathan, Kieran F. Docherty et al. profile →
  4. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
    2009 436 citations Marvin A. Konstam, James D. Neaton et al. profile →
  5. A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)
    2019 259 citations John J.V. McMurray, Silvio E. Inzucchi et al. European Journal of Heart Failure profile →
  6. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
    2021 182 citations Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure profile →
  7. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
    2021 140 citations James P. Curtain, Kieran F. Docherty et al. European Heart Journal profile →
  8. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
    2021 130 citations Pardeep S. Jhund, Kieran F. Docherty et al. JAMA Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Felipe A. Martínez United States 29 5.3k 4.2k 1.8k 1.5k 1.2k 100 7.9k
A.J. Pérez Pérez United States 6 7.0k 1.3× 4.1k 1.0× 1.9k 1.1× 2.0k 1.3× 1.2k 1.0× 11 9.6k
Martin Lefkowitz United States 55 10.0k 1.9× 2.6k 0.6× 1.6k 0.9× 2.4k 1.6× 841 0.7× 172 12.7k
Søren Lund Kristensen Denmark 36 2.9k 0.5× 2.7k 0.6× 1.3k 0.7× 530 0.4× 1.2k 1.0× 134 6.4k
Barbara Roniker United States 16 4.0k 0.8× 3.9k 0.9× 1.6k 0.9× 1.2k 0.8× 958 0.8× 20 6.2k
Michael G. Silverman United States 22 2.0k 0.4× 4.5k 1.1× 2.6k 1.5× 706 0.5× 1.9k 1.6× 44 6.8k
Marjorie Gatlin United States 10 4.0k 0.8× 3.1k 0.7× 1.3k 0.7× 821 0.6× 748 0.6× 16 5.7k
María Lorenza Muiesan Italy 46 5.1k 1.0× 1.9k 0.5× 1.3k 0.7× 690 0.5× 569 0.5× 260 7.4k
Harry Shi United States 23 3.1k 0.6× 1.9k 0.5× 905 0.5× 1.1k 0.7× 541 0.5× 56 4.6k
Jay H. Kleiman United States 14 3.8k 0.7× 2.9k 0.7× 1.4k 0.8× 965 0.7× 736 0.6× 20 5.5k
Anna Norhammar Sweden 38 2.5k 0.5× 4.1k 1.0× 1.1k 0.6× 335 0.2× 1.5k 1.3× 133 6.1k

Countries citing papers authored by Felipe A. Martínez

Since Specialization
Citations

This map shows the geographic impact of Felipe A. Martínez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felipe A. Martínez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felipe A. Martínez more than expected).

Fields of papers citing papers by Felipe A. Martínez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felipe A. Martínez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felipe A. Martínez. The network helps show where Felipe A. Martínez may publish in the future.

Co-authorship network of co-authors of Felipe A. Martínez

This figure shows the co-authorship network connecting the top 25 collaborators of Felipe A. Martínez. A scholar is included among the top collaborators of Felipe A. Martínez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felipe A. Martínez. Felipe A. Martínez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kondo, Toru, Pardeep S. Jhund, Inder S. Anand, et al.. (2025). Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF. JACC Heart Failure. 13(6). 927–939. 2 indexed citations
2.
Vaduganathan, Muthiah, Brian Claggett, Safia Chatur, et al.. (2025). Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction. Nature Medicine. 32(1). 325–331.
3.
4.
Ostrominski, John W., Mats Christian Højbjerg Lassen, Brian Claggett, et al.. (2024). Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. European Heart Journal. 46(14). 1321–1331. 3 indexed citations
5.
Vardeny, Orly, Akshay S. Desai, Pardeep S. Jhund, et al.. (2024). Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology. 9(3). 283–283. 16 indexed citations
6.
Dorian, Paul, Benoit Coutu, James E. Ip, et al.. (2023). MP-453091-1 EFFECT OF ETRIPAMIL NASAL SPRAY ON VENTRICULAR RATE IN PATIENTS EXPERIENCING SYMPTOMATIC ATRIAL FIBRILLATION. Heart Rhythm. 20(5). S109–S109. 1 indexed citations
7.
Chatur, Safia, Muthiah Vaduganathan, Brian Claggett, et al.. (2023). Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation. 148(22). 1735–1745. 19 indexed citations
8.
Ostrominski, John W., Muthiah Vaduganathan, Senthil Selvaraj, et al.. (2023). Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation. 148(24). 1945–1957. 11 indexed citations
9.
Kondo, Toru, Karola Jering, Pardeep S. Jhund, et al.. (2023). Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation. Circulation Heart Failure. 16(7). e010377–e010377. 3 indexed citations
10.
Kondo, Toru, Karola Jering, C. Jan Willem Borleffs, et al.. (2023). Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 147(14). 1067–1078. 5 indexed citations
11.
Yeoh, Su Ern, Kieran F. Docherty, Ross T. Campbell, et al.. (2023). Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 147(22). 1670–1683. 24 indexed citations
12.
Kondo, Toru, Jawad H. Butt, James P. Curtain, et al.. (2023). Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure. 16(12). e010898–e010898. 3 indexed citations
13.
Chatur, Safia, Jonathan W. Cunningham, Muthiah Vaduganathan, et al.. (2023). Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with mildly reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial. European Journal of Heart Failure. 25(7). 1170–1175. 15 indexed citations
14.
Santi, Ricardo López, Felipe A. Martínez, Adrián Baranchuk, et al.. (2021). Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. European Cardiology Review. 16. e16–e16. 1 indexed citations
15.
Heerspink, Hiddo J.L., Remo Holanda de Mendonça Furtado, Otávio Berwanger, et al.. (2021). Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: Results from the DARE-19 Randomized Controlled Trial. Journal of the American Society of Nephrology. 32(10S). B5–B6. 2 indexed citations
16.
Kiernan, Michael S., Deborah Wentworth, Gary S. Francis, et al.. (2012). Predicting Adverse Events During Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. European Journal of Heart Failure. 14(12). 1401–1409. 25 indexed citations
17.
18.
Konstam, Marvin A., Philip A. Poole‐Wilson, Kenneth Dickstein, et al.. (2008). Design of the Heart Failure Endpoint Evaluation of AII-Antagonist Losartan (HEAAL) Study in Patients Intolerant to ACE-Inhibitor. European Journal of Heart Failure. 10(9). 899–906. 12 indexed citations
19.
Martínez, Felipe A. & Jorge Thierer. (2006). Todos los pacientes con insuficiencia cardíaca y función sistólica conservada o levemente deprimida deben recibir antagonistas de la aldosterona. Revista Argentina de Cardiología. 74(5). 389–395. 1 indexed citations
20.
Pitt, Bertram, Harvey D. White, José Carlos Nicolau, et al.. (2005). Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. Journal of the American College of Cardiology. 46(3). 425–431. 266 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A.J. Pérez Pérez Breakdown of academic impact, for papers by Martin Lefkowitz Breakdown of academic impact, for papers by Søren Lund Kristensen Breakdown of academic impact, for papers by Barbara Roniker Breakdown of academic impact, for papers by Michael G. Silverman Breakdown of academic impact, for papers by Marjorie Gatlin Breakdown of academic impact, for papers by María Lorenza Muiesan Breakdown of academic impact, for papers by Harry Shi Breakdown of academic impact, for papers by Jay H. Kleiman Breakdown of academic impact, for papers by Anna Norhammar
Rankless by CCL
2026